For Industry


Boston Children’s is home to the world's largest research enterprise based at a pediatric hospital. More than 1,300 scientists comprise our research community, including seven members of the National Academy of Sciences, 12 members of the Institute of Medicine, 14 members of the Howard Hughes Medical Institute and 28 members of the American Society for Clinical Investigation. Our research facilities include more than 800,000 square feet of basic and translational research space and 50,000 square feet of clinical research space. Our current initiatives have attracted a record $308 million in annual funding, including more federal funding than any other pediatric center.

Major areas of research strengths include Vascular Biology, Stem Cell Biology, Neurology, Informatics and Genomics. Being a world-renowned academic research hospital, we have the infrastructure to develop technologies from the lab and bring them through clinical trials and to the patient. Specific focus areas for translational medicine are in hematology/oncology, inherited immunodeficiencies, cardiology, autism and related developmental disorders through the Translational Research Program and the study and treatment of rare and orphan diseases, through the Manton Center for Orphan Disease Research. Boston Children’s is a partner of choice for projects at all stages of research and development. Our investigators know unmet medical needs first-hand, because they see them daily in their practice. With infrastructure to collect tissues and DNA samples from most of our patients in many different departments, Boston Children’s has a large and well maintained tissue repository that is a source for determination of biomarkers and therapeutic targets, and ultimately an enhanced understanding of disease, particularly the rare and genetic disorders that are well represented in our clinics.

It is the mission of the Technology and Innovation Development Office (TIDO) to maximize the impact of Boston Children’s innovations on patient health while enhancing the research endeavor.

TIDO utilizes a three pronged approach to accomplish this mission:

    With an annual research base of ~ $301M, Boston Children’s Hospital researchers generate an average of 150 new invention disclosures per year. These innovations are evaluated by the Patents and Licensing Group for patentability and ultimately marketed and licensed to strong and committed commercial partners. This has generated 250 active licenses and numerous products currently on the market—generating ~$7M in gross revenue per year that fuels the research enterprise and further innovation.
    With approximately 200 collaborations with industry over the past five years, Boston Children’s Hospital is a partner of choice for companies wishing to collaborate with our nationally recognized researchers and clinicians. Business Development within TIDO enables R&D collaborations with industry partners by matching parties with complementary objectives and resources—creating partnerships at all stages of research, development, and pre-clinical and clinical investigation.
    Boston Children’s Hospital launched a Technology Development Fund in early 2009 aimed at advancing the stage of development of promising Boston Children’s Hospital technologies. With an external advisory board of industry leaders in pharmaceutical, biotechnology, device and diagnostic product development and a network of development partners and contract research organizations (CROs)— Boston Children’s Hospital is investing in the discoveries and innovations of its researchers to translate them into products.
Children's HospitalTerms and Conditions
Site Designed and Developed by Genuine